Xu Zhang

Xu Zhang

Auto-generated profile, based on publicly available information

Xu Zhang

Division of Hematology & Oncology, Department of Medicine University of Illinois at Chicago Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
GPGrier Page
Grier Page
TKTamir Kanias
Tamir Kanias
YGYuelong J. Guo
Yuelong J. Guo
MLMarion C. Lanteri
Marion C. Lanteri
XZXu Zhang
Xu Zhang
MGMark T. Gladwin
Mark T. Gladwin
Background. The evolutionary pressure of endemic malaria and other erythrocytic pathogens has shaped variation in genes encoding erythrocyte structural and functional proteins, influencing responses to hemolytic stress during transfusion and disease. Methods. We sought to identify such genetic variants in blood donors by conducting a genome-wide association study (GWAS) of 12,353 volunteer donors, including 1,406 African Americans, 1,306 Asians, and 945 Hispanics, whose stored erythrocytes were characterized by quantitative assays of in vitro osmotic, oxidative, and cold-storage hemolysis. Results. GWAS revealed 27 significant loci (P < 5 × 10–8), many in candidate genes known to modulate erythrocyte structure, metabolism, and ion channels, including SPTA1, ALDH2, ANK1, HK1, MAPKAPK5, AQP1, PIEZO1, and SLC4A1/band 3. GWAS of oxidative hemolysis identified variants in genes encoding antioxidant enzymes, including GLRX, GPX4, G6PD, and SEC14L4 (Golgi-transport protein). Genome-wide significant loci were also tested for association with the severity of steady-state (baseline) in vivo hemolytic anemia in patients with sickle cell disease, with confirmation of identified SNPs in HBA2, G6PD, PIEZO1, AQP1, and SEC14L4. Conclusions. Many of the identified variants, such as those in G6PD, have previously been shown to impair erythrocyte recovery after transfusion, associate with anemia, or cause rare Mendelian human hemolytic diseases. Candidate SNPs in these genes, especially in polygenic combinations, may affect RBC recovery after transfusion and modulate disease severity in hemolytic diseases, such as sickle cell disease and malaria.

1 February 2017 in Translational Research
Verified
Journal Article
Closed access
KSKeely L. Szilágyi
Keely L. Szilágyi
CLCong Liu
Cong Liu
XZXu Zhang
Xu Zhang
TWTing Wang
Ting Wang
JFJeffrey D. Fortman
Jeffrey D. Fortman
JGJoe G.N. Garcia
Joe G.N. Garcia

26 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ASAlexei J. Stuckel
Alexei J. Stuckel
WZWei Zhang
Wei Zhang
XZXu Zhang
Xu Zhang
SZShuai Zeng
Shuai Zeng
UDUrszula Dougherty
Urszula Dougherty
SKSharad Khare
Sharad Khare
In colorectal cancer (CRC), upregulation of the C-X-C motif chemokine receptor 4 (CXCR4) is correlated with metastasis and poor prognosis, highlighting the need to further elucidate CXCR4’s regulation in CRC. For the first time, DNA methylation and 5-hydroxymethylcytosine aberrations were investigated to better understand the epigenetic regulation of CXCR4 in CRC. CXCR4 expression levels were measured using qPCR and immunoblotting in normal colon tissues, primary colon cancer tissues and CRC cell lines. Publicly available RNA-seq and methylation data from The Cancer Genome Atlas (TCGA) were extracted from tumors from CRC patients. The DNA methylation status spanning CXCR4 gene was evaluated using combined bisulfite restriction analysis (COBRA). The methylation status in the CXCR4 gene body was analyzed using previously performed nano-hmC-seal data from colon cancers and adjacent normal colonic mucosa. CXCR4 expression levels were significantly increased in tumor stromal cells and in tumor colonocytes, compared to matched cell types from adjacent normal-appearing mucosa. CXCR4 promoter methylation was detected in a minority of colorectal tumors in the TCGA. The CpG island of the CXCR4 promoter showed increased methylation in three of four CRC cell lines. CXCR4 protein expression differences were also notable between microsatellite stable (MSS) and microsatellite instable (MSI) tumor cell lines. While differential methylation was not detected in CXCR4, enrichment of 5-hydroxymethylcytosine (5hmC) in CXCR4 gene bodies in CRC was observed compared to adjacent mucosa.

12 July 2023 in American Journal of Hematology
Verified
Journal Article
Open access
BSBinal N. Shah
Binal N. Shah
XZXu Zhang
Xu Zhang
ASAdelina I. Sergueeva
Adelina I. Sergueeva
GMGalina Y. Miasnikova
Galina Y. Miasnikova
TGTomas Ganz
Tomas Ganz
VGVictor R. Gordeuk
Victor R. Gordeuk
Von Hippel–Lindau protein (VHL) is essential to hypoxic regulation of cellular processes. VHL promotes proteolytic clearance of hypoxia‐inducible transcription factors (HIFs) that have been modified by oxygen‐dependent HIF‐prolyl hydroxylases. A homozygous loss‐of‐function VHLR200W mutation causes Chuvash erythrocytosis, a congenital disorder caused by augmented hypoxia‐sensing. Homozygous VHLR200W results in accumulation of HIFs that increase transcription of the erythropoietin gene and raise hematocrit. Phlebotomies reduce hematocrit and hyperviscosity symptoms. However, the major cause of morbidity and mortality in Chuvash erythrocytosis is thrombosis. Phlebotomies cause iron deficiency, which may further elevate HIF activity and transferrin, the HIF‐regulated plasma iron transporter recently implicated in thrombogenesis. We hypothesized that transferrin is elevated in Chuvash erythrocytosis, and that iron deficiency contributes to its elevation and to thrombosis. We studied 155 patients and 154 matched controls at steady state and followed them for development of thrombosis. Baseline transferrin was elevated, and ferritin reduced in patients. VHLR200W homozygosity and lower ferritin correlated with higher erythropoietin and transferrin. During 11 years of follow‐up, risk of thrombosis increased 8.9‐fold in patients versus controls. Erythropoietin elevation, but not hematocrit or ferritin, correlated with thrombosis risk. Unexpectedly, transferrin elevation associated with reduced rather than increased thrombosis risk. The A allele of the promoter EPO single nucleotide polymorphisms (SNP), rs1617640, associated with elevated erythropoietin and increased thrombosis risk, whereas the A allele of the intronic TF SNP, rs3811647, associated with higher transferrin and protection from thrombosis in patients. Our findings suggest an unexpected causal relationship between increased transferrin and protection from thrombosis in Chuvash erythrocytosis.

22 July 2020 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
VGVictor R. Gordeuk
Victor R. Gordeuk
BSBinal N. Shah
Binal N. Shah
XZXu Zhang
Xu Zhang
PTPhilip E. Thuma
Philip E. Thuma
SZStenford Zulu
Stenford Zulu
JPJosef Prchal
Josef Prchal

2 October 2021 in Cells
Verified
Journal Article
Open access
PDF file
ASAlexei J. Stuckel
Alexei J. Stuckel
SZShuai Zeng
Shuai Zeng
ZLZhen Lyu
Zhen Lyu
WZWei Zhang
Wei Zhang
XZXu Zhang
Xu Zhang
SKSharad Khare
Sharad Khare
Conventional wisdom is that Sprouty2 (SPRY2), a suppressor of Receptor Tyrosine Kinase (RTK) signaling, functions as a tumor suppressor and is downregulated in many solid tumors. We reported, for the first time, that increased expression of SPRY2 augments cancer phenotype and Epithelial-Mesenchymal-Transition (EMT) in colorectal cancer (CRC). In this report, we assessed epigenetic DNA modifications that regulate SPRY2 expression in CRC. A total of 4 loci within SPRY2 were evaluated for 5mC using Combined Bisulfite Restriction Analysis (COBRA). Previously sequenced 5hmC nano-hmC seal data within SPRY2 promoter and gene body were evaluated in CRC. Combined bioinformatics analyses of SPRY2 CRC transcripts by RNA-seq/microarray and 450K methyl-array data archived in The Cancer Genome Atlas (TCGA) and GEO database were performed. SPRY2 protein in CRC tumors and cells was measured by Western blotting. Increased SPRY2 mRNA was observed across several CRC datasets and increased protein expression was observed among CRC patient samples. For the first time, SPRY2 hypomethylation was identified in adenocarcinomas in the promoter and gene body. We also revealed, for the first time, increases of 5hmC deposition in the promoter region of SPRY2 in CRC. SPRY2 promoter hypomethylation and increased 5hmC may play an influential role in upregulating SPRY2 in CRC.